ACCME won't ban industry funding of CME

Share this article:
The Accreditation Council for Continuing Medical Education (ACCME) said that for the time being, it won't ban commercial support of CME.

The ACCME had posed a ban as one possible solution to concerns about the independence of CME from industry influence and issued a call for comment. Having thought about it, the accrediting body's board said it feels its Standards of Commercial Support are an adequate safeguard against commercial bias.

“Of course, the ACCME reserves the right to re-evaluate this position from time to time, but at this point, no action will be taken,” said the board's executive summary. The organization is developing an “enhanced monitoring system” to be rolled out this year and next that includes direct observation of CME activities by volunteer monitors.

Advocates of continued commercial support for CME from industry were jubilant.

“It shows the ACCME is paying attention to what all the parties involved in CME are saying,” said Tom Sullivan, president of med ed firm Rockpointe and author of the Policy and Medicine blog. “There was overwhelming support for commercial support among both providers and physicians in the comments.”

John Kamp, executive director of the Coalition for Healthcare Communication, said: "These decisions demonstrate that a significant body of CME leaders from academic, hospital and government organizations believes that commercial support for CME provides a great benefit for physician learners and their patients. While Macy, journal editors, academics and other 'scholars' campaign to eliminate commercial support from their lofty perches, the folks with experience and expertise getting these programs done focus on improvements that advance patient care rather the pursuit of academic purity."

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...